Jefferies Group Analysts Give Pfizer (PFE) a $38.00 Price Target

Jefferies Group set a $38.00 target price on Pfizer (NYSE:PFE) in a research note issued to investors on Friday. The firm currently has a hold rating on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Pfizer’s Q1 2018 earnings at $0.73 EPS, FY2020 earnings at $3.18 EPS, FY2021 earnings at $3.49 EPS and FY2022 earnings at $3.89 EPS.

Other research analysts have also issued reports about the company. Vetr raised Pfizer from a hold rating to a buy rating and set a $37.98 price objective on the stock in a research report on Monday, January 8th. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a buy rating in a research report on Monday, January 8th. Morgan Stanley set a $41.00 price objective on Pfizer and gave the company a buy rating in a research report on Friday, January 5th. Zacks Investment Research raised Pfizer from a hold rating to a buy rating and set a $41.00 price objective on the stock in a research report on Wednesday, January 17th. Finally, Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the company a buy rating in a research report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. Pfizer presently has a consensus rating of Hold and a consensus price target of $39.20.

How to Become a New Pot Stock Millionaire

Shares of Pfizer stock opened at $36.32 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer has a twelve month low of $31.67 and a twelve month high of $39.43. The firm has a market capitalization of $216,208.05, a P/E ratio of 13.71, a PEG ratio of 1.81 and a beta of 0.90.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same period last year, the company posted $0.47 earnings per share. The firm’s revenue was up .6% compared to the same quarter last year. equities research analysts predict that Pfizer will post 2.96 EPS for the current year.

Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

In other news, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the sale, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now directly owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,037 shares of company stock worth $9,064,785. Corporate insiders own 0.06% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in PFE. Earnest Partners LLC bought a new stake in Pfizer in the fourth quarter valued at about $105,000. First Dallas Securities Inc. bought a new stake in Pfizer in the fourth quarter valued at about $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Pfizer in the fourth quarter valued at about $118,000. Delpha Capital Management LLC bought a new stake in Pfizer in the fourth quarter valued at about $126,000. Finally, Americafirst Capital Management LLC bought a new stake in Pfizer in the third quarter valued at about $127,000. 71.21% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.chaffeybreeze.com/2018/04/16/jefferies-group-analysts-give-pfizer-pfe-a-38-00-price-target.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply